<SEC-DOCUMENT>0001062993-21-011100.txt : 20211117
<SEC-HEADER>0001062993-21-011100.hdr.sgml : 20211117
<ACCEPTANCE-DATETIME>20211117201915
ACCESSION NUMBER:		0001062993-21-011100
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20211115
FILED AS OF DATE:		20211117
DATE AS OF CHANGE:		20211117

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			McIlwain Matthew S
		CENTRAL INDEX KEY:			0001381752

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39434
		FILM NUMBER:		211422272

	MAIL ADDRESS:	
		STREET 1:		1000 SECOND AVENUE
		STREET 2:		SUITE 3700
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98104

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nautilus Biotechnology, Inc.
		CENTRAL INDEX KEY:			0001808805
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		2701 EASTLAKE AVE EAST
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98102
		BUSINESS PHONE:		206-333-2001

	MAIL ADDRESS:	
		STREET 1:		2701 EASTLAKE AVE EAST
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98102

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARYA Sciences Acquisition Corp III
		DATE OF NAME CHANGE:	20200408
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>form4.xml
<DESCRIPTION>STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2021-11-15</periodOfReport>

    <issuer>
        <issuerCik>0001808805</issuerCik>
        <issuerName>Nautilus Biotechnology, Inc.</issuerName>
        <issuerTradingSymbol>NAUT</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001381752</rptOwnerCik>
            <rptOwnerName>McIlwain Matthew S</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O MADRONA VENTURE GROUP</rptOwnerStreet1>
            <rptOwnerStreet2>999 THIRD AVENUE, 34TH FLOOR</rptOwnerStreet2>
            <rptOwnerCity>SEATTLE</rptOwnerCity>
            <rptOwnerState>WA</rptOwnerState>
            <rptOwnerZipCode>98104</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2021-11-15</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>P</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>100000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>5.2989</value>
                    <footnoteId id="F1"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>459075</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>5798394</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>By Madrona Venture Fund VI, LP</value>
                    <footnoteId id="F2"/>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>222376</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>By Madrona Venture Fund VI-A, LP</value>
                    <footnoteId id="F3"/>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $5.16 to $5.36, inclusive. The reporting person undertakes to provide to Nautilus Biotechnology, Inc., any security holder of Nautilus Biotechnology, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.</footnote>
        <footnote id="F2">Shares held by Madrona Venture Fund VI, LP (&quot;Madrona Fund VI&quot;). Madrona Investment Partners VI, L.P. (&quot;Madrona Partners VI&quot;) is the general partner of Madrona Fund VI, and Madrona VI General Partner, LLC (&quot;Madrona VI LLC&quot;) is the general partner of Madrona Partners VI. The reporting person, is a managing member of Madrona VI LLC. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.</footnote>
        <footnote id="F3">Shares held by Madrona Venture Fund VI-A, LP (&quot;Madrona Fund VI-A&quot;). Madrona Partners VI is the general partner of Madrona Fund VI-A, and Madrona VI LLC is the general partner of Madrona Partners VI. The reporting person, is a managing member of Madrona VI LLC. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of benefical ownership of all of the reported shares for purposes of Section 16 or for any other purpose.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Matthew McIlwain</signatureName>
        <signatureDate>2021-11-17</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
